What was the first approval date for Keytruda?
Keytruda, also known as pembrolizumab, was first approved by the US Food and Drug Administration (FDA) on September 4, 2014, for the treatment of patients with unresectable or metastatic melanoma who have a certain type of genetic mutation, as identified by a companion diagnostic test. This was the medication's first approval, and it paved the way for further approvals in other disease areas [1].
How has Keytruda's approval timeline expanded since its initial approval?
Since its initial approval, Keytruda has been approved for the treatment of several other types of cancer, including non-small cell lung cancer, head and neck cancer, and urothelial carcinoma, among others. The FDA has also approved Keytruda in combination with other medications for the treatment of certain types of cancer, expanding its indications and uses [1].
What are the patents for Keytruda?
Keytruda is a commercial product of Merck & Co., Inc., and as such, it has a number of patents associated with it. According to DrugPatentWatch.com, the first key patent for Keytruda, US 9132292, was filed on August 29, 2007, and was granted on September 22, 2015. This patent covers the method of treating cancer with pembrolizumab, the active ingredient in Keytruda [2].
How has Keytruda impacted the cancer treatment landscape?
Since its approval, Keytruda has become a cornerstone in the treatment of several types of cancer. Its efficacy and safety have been demonstrated in numerous clinical trials, and it has become a widely prescribed medication for patients with unresectable or metastatic melanoma, non-small cell lung cancer, and other types of cancer [1].
Sources:
[1] US Food and Drug Administration. (2014). Keytruda Approval.
[2] DrugPatentWatch.com. (n.d.). US Patent 9132292.
[3] Merck & Co., Inc. (n.d.). Keytruda.